Pliant Therapeutics, Inc.
HealthcareNASDAQ:PLRX · NASDAQ Global Select
-$0.01 today
Vol 0.21M · Avg 0.52M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-82.4%
avg 297.0%
ROIC
-71.4%
avg -96.6%
ROA
-66.3%
avg -67.2%
Analysis
ROA is currently the strongest return metric at -66.3% versus its period average of -67.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bernard Coulie | President, Chief Executive Officer & Director | $938,901.00 | — | 60 | $440,000.00 | 0.71% |
Keith Lamont Cummings | Chief Financial Officer | $820,201.00 | — | 49 | $124,000.00 | 0.20% |
Minnie Kuo | Chief Operating Officer | $774,470.00 | — | 45 | $0.00 | <0.01% |
Rik Derynck | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Dean Sheppard | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Hal Chapman | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Tim Machajewski | Senior VP & Head of Research | — | — | — | — | — |
Monica Sandberg | Vice President, Regulatory & Compliance | — | — | — | — | — |
Christopher S. Keenan | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Delphine Imbert | Chief Technical Officer | — | — | — | — | — |
Lily Cheung | Chief Human Resources Officer | — | — | 53 | $123,000.00 | 0.20% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$163,619.84
Net Sentiment
$163,619.84
Net selling
Most Active
Cummings Keith Lamont
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 4 sells worth $163,619.84 over the last 12 months. That adds up to net selling of $163,619.84. Cummings Keith Lamont was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +34.3% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +34.3% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Clene Inc.
NASDAQ:CLNN
$60.20M
Who manages PLRX?
Pliant Therapeutics, Inc. (PLRX) lists 11 active executives. The top listed executive is Bernard Coulie, President, Chief Executive Officer & Director.
Are PLRX insiders buying or selling?
Recent insider activity shows net selling of $24.72M.
Explore More
Continue the stock analysis
Jump to another research area for this company.